[
  {
    "ts": "2025-11-06T08:04:00+00:00",
    "headline": "Novo Nordisk CFO outlines ‘ultimate defense’ against stock downgrades and lawsuits to retain weight-loss crown",
    "summary": "\"The ultimate defence in our industry is in innovation,\" Knudsen told Fortune in an exclusive interview.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
    "source": "Fortune",
    "provider": "yfinance",
    "raw": {
      "id": "5848522d-6379-3c44-88b1-55d6477f7e91",
      "content": {
        "id": "5848522d-6379-3c44-88b1-55d6477f7e91",
        "contentType": "STORY",
        "title": "Novo Nordisk CFO outlines ‘ultimate defense’ against stock downgrades and lawsuits to retain weight-loss crown",
        "description": "",
        "summary": "\"The ultimate defence in our industry is in innovation,\" Knudsen told Fortune in an exclusive interview.",
        "pubDate": "2025-11-06T08:04:00Z",
        "displayTime": "2025-11-06T08:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4",
          "originalWidth": 2048,
          "originalHeight": 1365,
          "caption": "Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M_qy5Z_He6HZ19cMidPX0w--~B/aD0xMzY1O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4.cf.webp",
              "width": 2048,
              "height": 1365,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JRApwcThX.P.KPvduaht_Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Fortune",
          "url": "http://fortune.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T10:47:09+00:00",
    "headline": "Impressive Earnings May Not Tell The Whole Story For Eli Lilly (NYSE:LLY)",
    "summary": "Unsurprisingly, Eli Lilly and Company's ( NYSE:LLY ) stock price was strong on the back of its healthy earnings report...",
    "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b849e098-f319-3b50-b156-6496ffe1509d",
      "content": {
        "id": "b849e098-f319-3b50-b156-6496ffe1509d",
        "contentType": "STORY",
        "title": "Impressive Earnings May Not Tell The Whole Story For Eli Lilly (NYSE:LLY)",
        "description": "",
        "summary": "Unsurprisingly, Eli Lilly and Company's ( NYSE:LLY ) stock price was strong on the back of its healthy earnings report...",
        "pubDate": "2025-11-06T10:47:09Z",
        "displayTime": "2025-11-06T10:47:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:58:55+00:00",
    "headline": "Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift",
    "summary": "Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.",
    "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "da465711-34fe-3aef-ba8a-0193b69d9344",
      "content": {
        "id": "da465711-34fe-3aef-ba8a-0193b69d9344",
        "contentType": "STORY",
        "title": "Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift",
        "description": "",
        "summary": "Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.",
        "pubDate": "2025-11-06T12:58:55Z",
        "displayTime": "2025-11-06T12:58:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T11:45:00+00:00",
    "headline": "Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using th",
    "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "57994221-aaeb-3d62-b328-698a7835bfe5",
      "content": {
        "id": "57994221-aaeb-3d62-b328-698a7835bfe5",
        "contentType": "STORY",
        "title": "Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using th",
        "pubDate": "2025-11-06T11:45:00Z",
        "displayTime": "2025-11-06T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]